About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lung Cancer Clinical Trials in Chicago | 561 Studies

Clinical Trials Lung CancerChicago

Lung Cancer Clinical Trials in Chicago

Find 561 clinical trials for lung cancer near Chicago, Illinois. Connect with research centers in your area.

All Lung Cancer trials nationwide All trials in Chicago

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 461-480 of 561 trials

CompletedStudy of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)The purpose of this study is to evaluate the effect of the ABT-869 on the NSCLC subjects.NCT00517790·Fountain Valley, California and 27 others Active not recruitingA Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022.NCT02817633·Goodyear, Arizona and 88 others

Lung Cancer Trials in Other Cities

New York Los Angeles Houston Phoenix Philadelphia San Antonio

Data from ClinicalTrials.govTerms

CompletedErlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLCThis will be the first prospective study where patients will be selected on the basis of two measures of the epidermal growth factor receptor (EGFR) pathway.NCT00294762·Alhambra, California and 42 others

CompletedLymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung CancerRATIONALE: Surgical removal of all lymph nodes in the chest may kill cancer cells that have spread from tumors in the lung.NCT00003831·Mobile, Alabama and 73 others

TerminatedTIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed TherapyThe purpose of this study is to compare the safety and anti-tumor effect of rociletinib with erlotinib in patients whose tumors have specific EGFR mutations and who have not…NCT02186301·Birmingham, Alabama and 73 others

TerminatedA Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid TumorsThe purpose of this study is to assess the safety and antitumor activity of INCB001158 plus epacadostat, with or without pembrolizumab, in participants with advanced or metastatic…NCT03361228·Birmingham, Alabama and 1 other

Active not recruitingTepotinib Phase II in NSCLC Harboring MET Alterations (VISION)This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer.NCT02864992·Duarte, California and 175 others

CompletedOltipraz in the Prevention of Lung Cancer in People Who SmokeRATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer.NCT00006457·Chicago, Illinois and 1 other

CompletedDose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid TumorsA first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid…NCT05479812·Scottsdale, Arizona and 13 others

CompletedA Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) MutationThis multicenter, randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of onartuzumab in combination with erlotinib in patients with previously…NCT01887886·Bakersfield, California and 34 others

CompletedS0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung CancerRATIONALE: Studying samples of blood and tissue from smokers (closed to entry as of 7/15/07) and non-smokers with cancer in the laboratory may help doctors learn more about…NCT00450281·Anchorage, Alaska and 404 others

CompletedCombination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)This phase II LUNG-MAP treatment trial studies how well combination treatment (talazoparib plus avelumab) works in treating patients with non-squamous non-small cell lung cancer…NCT04173507·Mobile, Alabama and 324 others

TerminatedGemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung CancerRATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or…NCT01041781·Anniston, Alabama and 399 others

CompletedA Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)This randomized, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with Tarceva (erlotinib) in…NCT01456325·Chandler, Arizona and 212 others

RecruitingImmunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP TrialThis phase II trial tests the impact of biomarkers in predicting initial treatment (first-line) PD1 or PD-L1 (PD\[L\]-1)-based immunotherapy response and in selecting second-line…NCT07288034·Goodyear, Arizona and 12 others

Active not recruitingHER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung CancerThis study includes a Dose Escalation Part to identify the recommended combination dose (RCD) and a Dose Expansion Part to further evaluate efficacy and safety.NCT04676477·Santa Monica, California and 30 others

RecruitingLung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerThis screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and…NCT03851445·Birmingham, Alabama and 1228 others

RecruitingComparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer…NCT05642572·Daphne, Alabama and 453 others

Active not recruitingStudy of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or metastatic (cancer that has…NCT05089734·Anchorage, Alaska and 226 others

CompletedMifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid TumorsThis is a study to assess the safety of the combination of mifepristone and eribulin in patients with metastatic or locally advanced unresectable breast or other specified solid…NCT02014337·Tucson, Arizona and 10 others

PreviousPage 24 of 29Next

Other Conditions in Chicago

Breast Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma